By the num­bers: 2-year tal­ly of Cel­gene's biotech part­ner­ship deals tops $3B in cash

Bob Hug­in and his busy deal­mak­ing wiz George Golumbes­ki have po­si­tioned Cel­gene as an in­dus­try-lead­ing wheel­er and deal­er.

$1 bil­lion to part­ner with Juno on CAR-T? OK. $200 mil­lion in cash to rewrite a pact with Agios? They’ll take that. An­oth­er $450 mil­lion to part­ner with As­traZeneca on its check­point? No prob­le­mo. As big­ger com­pa­nies fret­ted over the val­u­a­tions they were see­ing in the biotech boom, Cel­gene’s ex­ec­u­tive team were struck by the op­por­tu­ni­ties. “If we see them, we’re go­ing to go af­ter them at the right time,” Cel­gene CEO Bob Hug­in told me last sum­mer, af­ter grab­bing Re­cep­tos for its im­munol­o­gy pipeline for $7.2 bil­lion.

Any doubts on that score should have been laid to rest with their lat­est deal to mar­ry up with Jounce for $261 mil­lion in an up­front and eq­ui­ty in­vest­ment, a blend that Cel­gene has long liked. Golumbes­ki is al­so a known fan of the op­tion agree­ment.

To give you a bet­ter idea of just how pro­lif­ic Cel­gene has been in re­cent years, we asked RBC’s Michael Yee if we could share his chart col­lec­tion of Cel­gene’s part­ner­ship deals. To put this in some per­spec­tive, we know from the com­pa­ny’s state­ments that it has com­mit­ted $3.2 bil­lion in cash for Yee’s list of pacts just over the past two years.

That’s more than what Gilead spent for all of R&D in 2015.

There’s al­so at least $5 bil­lion in mile­stones to con­sid­er (Cel­gene doesn’t re­lease every fig­ure tied to a deal). In­ter­est­ing­ly, that ra­tio of cash to mile­stones helps il­lus­trate why biotech com­pa­nies are so joy­ful when they see Golumbes­ki at the deal ta­ble. It al­so doesn’t hurt that Cel­gene typ­i­cal­ly leaves its part­ners in charge of the in­no­va­tion de­vel­op­ment work need­ed to be done.


Here’s a list of se­lect Cel­gene part­nered pro­grams:

Jounce Ther­a­peu­tics Jul-16 JTX-2011 + suc­ces­sor Im­muno‐on­col­o­gy
Nurix Sep‐15 Small Mol­e­cule Drug Dis­cov­ery On­col­o­gy, In­flam­ma­tion, Im­munol­o­gy
Epizyme Jul‐15 (+1) 3 Pre­de­fined Tar­gets; DOTL1 To be De­ter­mined; MLL
Juno Ther­a­peu­tics Jun‐15 CD19 and CD22 CAR‐T Can­cer, Au­toim­mune Dis­eases
Lyc­era Jun‐15 LYC‐30937 Im­muno‐on­col­o­gy
As­traZeneca Apr‐15 ME­DI4736 Can­cer Hema­tol­ogy
Zymeworks Jan‐15
Sutro Bio­phar­ma Oct-14 (+1) An­ti­body Dis­cov­ery Undis­closed Im­muno‐on­col­o­gy
No­gra Phar­ma Apr‐14 GED‐0301 Crohn’s dis­ease
Abide Ther­a­peu­tics Feb‐14 AB101131; Drug Dis­cov­ery In­flam­ma­tion; Im­munol­o­gy
Nant­Bio­Science Jan‐14 NTB‐011, NTB‐010; nab‐based mol­e­cules Can­cer
On­coMed Dec‐13 Demi­cizum­ab; 6 an­ti‐CSC Prod­ucts Sol­id tu­mors, NSCLC, Pan­cre­at­ic
Phar­mAkea Oct‐13 Small‐mol­e­cule Dis­cov­ery Can­cer, Fi­brot­ic dis­ease
Adimab Aug‐13 An­ti­body Dis­cov­ery Undis­closed
Acety­lon Jul‐13 Ri­col­i­no­s­tat; ACY‐738 Can­cer; Hema­tol­ogy
Ar­ray Bio­phar­ma Jul‐13 In­flam­ma­tion
Ten­gion Jul‐13 Neo-Kid­ney Aug­ment Pro­gram CKD
Con­cert Phar­ma May‐13 CTP‐730 In­flam­ma­tion
FOR­MA ther­a­peu­tics Apr‐13 Pro­tein Home­osta­sis
Blue­Bird Bio Mar-13 (+2) CAR‐T Cell BC­MA Hema­tol­ogy
Presage Bio­sciences Mar‐13 Drug‐Dis­cov­ery Plat­form Sol­id tu­mors
Ven­tiRx Oct‐12 VTX‐2337 Sol­id tu­mors
In­hi­bRx Jun‐12 An­ti­body Dis­cov­ery Undis­closed
Anap­tys­Bio Apr‐12 An­ti­body Dis­cov­ery Can­cer, In­flam­ma­tion
Quan­ti­cel Phar­ma­ceu­ti­cals Nov‐11 Can­cer
Agios Apr-10 (+2) AG‐221, AG‐881 IDH2/pan Mu­tant Can­cers
GlobeIm­mune May‐09 GI‐6301, GI‐6207, GI‐4000 On­col­o­gy
Ac­celeron Feb‐08 So­tater­cept, Lus­pa­ter­cept Be­ta‐Tha­lassemia, MDS, CKD
Cour­tesy Michael Yee, RBC Cap­i­tal Mar­kets

 

And this is the slide from Cel­gene’s own deck show­ing off their part­ner­ing prowess:

Cel­gene 2016 JPM Pre­sen­ta­tion (pg 26)

Fol­low­ing news of job cuts in Eu­ro­pean R&D ops, Sanofi con­firms it’s of­fer­ing US work­ers an 'ear­ly ex­it'

Ear­li­er in the week we learned that Sanofi was bring­ing out the bud­get ax to trim 466 R&D jobs in Eu­rope, re­tool­ing its ap­proach to car­dio as re­search chief John Reed beefed up their work in can­cer and gene ther­a­pies. And we’re end­ing the week with news that the phar­ma gi­ant has al­so been qui­et­ly re­duc­ing staff in the US, tar­get­ing hun­dreds of jobs as the com­pa­ny push­es vol­un­tary buy­outs with a fo­cus on R&D sup­port ser­vices.

Roger Perlmutter. Merck via webcast

'Our lega­cy mat­ter­s': Mer­ck maps out Keytru­da king­dom while spot­light­ing ad­vances in vac­cines, hos­pi­tal care

“You can for the mo­ment stop tak­ing notes. You can put down your pens and your pad. I have no slides. I have no sub­stan­tive da­ta. I have no pitch.”

So be­gan Roger Perl­mut­ter’s brief ap­pear­ance on­stage at Mer­ck’s first in­vestor day in five years, where he dived in­to the com­pa­ny’s his­to­ry dat­ing back to 1933. The first em­ploy­ees at Mer­ck Re­search Lab­o­ra­to­ries, hand­picked by founder George W. Mer­ck, were crit­i­cal to Mer­ck’s abil­i­ty to achieve clin­i­cal and com­mer­cial suc­cess.

How small- to mid-sized biotechs can adopt pa­tient cen­tric­i­ty in their on­col­o­gy tri­als

By Lucy Clos­sick Thom­son, Se­nior Di­rec­tor of On­col­o­gy Pro­ject Man­age­ment, Icon

Clin­i­cal tri­als in on­col­o­gy can be cost­ly and chal­leng­ing to man­age. One fac­tor that could re­duce costs and re­duce bar­ri­ers is har­ness­ing the pa­tient voice in tri­al de­sign to help ac­cel­er­ate pa­tient en­roll­ment. Now is the time to adopt pa­tient-cen­tric strate­gies that not on­ly fo­cus on pa­tient needs, but al­so can main­tain cost ef­fi­cien­cy.

Why would the FDA ap­prove an­oth­er con­tro­ver­sial drug to spur a woman’s li­bido with these da­ta? And why no ex­pert pan­el re­view?

AMAG Pharmaceuticals’ newly approved drug for spurring women’s sexual desire may never make much money, but it’s a big hit at sparking media attention.

The therapy — Vyleesi (bremelanotide) — got the green light from regulators on Friday evening, swiftly lighting up a range of stories around the world, from The New York Times to The Guardian. Several headlines inevitably referred to it as the “female Viagra,” invoking Pfizer’s old erectile dysfunction blockbuster.

But the two drugs have little in common.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,300+ biopharma pros reading Endpoints daily — and it's free.

John Reed at JPM 2019. Jeff Rumans for Endpoints News

Sanofi's John Reed con­tin­ues to re­or­ga­nize R&D, cut­ting 466 jobs while boost­ing can­cer, gene ther­a­py re­search

The R&D reorganization inside Sanofi is continuing, more than a year after the pharma giant brought in John Reed to head the research arm of the Paris-based company.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,300+ biopharma pros reading Endpoints daily — and it's free.

Re­gen­eron/Sanofi's an­ti­body un­der­whelms in asth­ma study — shares of ri­val Anap­tys­Bio pay the price

Al­though ex­pec­ta­tions were mut­ed, Re­gen­eron $REGN and Sanofi’s $SNY ex­per­i­men­tal IL-33 an­ti­body has un­der­whelmed in a proof-of-con­cept mid-stage asth­ma tri­al. Al­though the drug sig­nif­i­cant­ly im­proved the loss of asth­ma con­trol and lung func­tion as a monother­a­py com­pared to a place­bo, its ef­fect was nei­ther su­pe­ri­or to the es­tab­lished Dupix­ent, nor of val­ue when com­bined with the IL-4/IL-13 treat­ment.

Green-light­ed in Japan, FDA quick­ly spurns Dai­ichi Sanky­o's flawed ap­pli­ca­tion for AML drug

Three days af­ter win­ning Japan­ese ap­proval for its acute myeloid leukemia drug quizar­tinib, Dai­ichi Sankyo is be­ing forced to en­dure an em­bar­rass­ing re­jec­tion at the hands of the FDA.

US reg­u­la­tors wast­ed no time in bat­ting back quizar­tinib af­ter first high­light­ing the messy da­ta in its ap­pli­ca­tion in an in­ter­nal re­view, that in turn per­suad­ed a large ma­jor­i­ty of out­side ex­perts to rec­om­mend a re­jec­tion for the drug, which tar­gets FLT3-ITD–pos­i­tive AML cas­es.

Which top 10 big phar­mas have the most to gain — or lose — over the next 5 years?

When Evaluate Pharma crunched the likely drug sales numbers for the big 10, 2 stood out. 

Takeda, with its big Shire buyout under its belt, is set to almost double its worldwide sales record for 2018 over 5 years, putting it in the big 10 — the 9th spot, to be exact — which is exactly where CEO Christophe Weber wants to be. 

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,300+ biopharma pros reading Endpoints daily — and it's free.

HIV, pneu­mo­coc­cal — and what? Mer­ck­'s un­ex­pect­ed pipeline high­light ex­cites a lit­tle biotech

In an R&D update dominated by oncology — mostly Keytruda, followed by Lynparza and Lenvima — Merck chose to highlight a program in sensory pathology, an HIV drug, and a group of pneumococcal vaccines. And that has made at least one biotech very happy.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,300+ biopharma pros reading Endpoints daily — and it's free.